Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Enlivex Therapeutics Ltd ENLV

Healthcare Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ENLV)

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Accesswire 1 day ago

Enlivex Adopts Bitcoin Treasury Reserve Strategy

GlobeNewswire 7 days ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

GlobeNewswire 13 days ago

Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

GlobeNewswire November 12, 2024

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra(TM) in Patients with Osteoarthritis

GlobeNewswire October 30, 2024

Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

GlobeNewswire September 26, 2024

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

GlobeNewswire September 24, 2024

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire August 30, 2024

Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis

GlobeNewswire July 23, 2024
View More News ››

Opinion & Analysis (NDAQ:ENLV)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ENLV)

Enlivex Receives Authorization from the Danish Medicines Age

Just In: $ENLV Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of...
whytestocks - September 26, 2024

BUY BUY BUY BUY BUY

Whytestock is right on the news this thing alocentra gonna be first and only fda approuved
Nibinator - June 26, 2024

Enlivex Announces the Dosing of the First Patient in a Rando

BREAKING NEWS: $ENLV Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating...
whytestocks - June 24, 2024

Enlivex CEO Issues Letter to Shareholders - Perspectives on

News; $ENLV Enlivex CEO Issues Letter to Shareholders - Perspectives on Recent EventsNes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) ...
whytestocks - April 29, 2024

H.C. Wainwright Article on Enlivex

Worth the read for investors and potential investors, https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-a-buy-rating-on-enlivex...
HariboSpeedPeak - July 21, 2022

Price Target $15

Bio Blast Pharma Ltd (NASDAQ:ORPN) had its "buy" rating reaffirmed by analysts at Roth Capital (     ). They now have...
Twistedsteel74 - June 13, 2016
View more Bullboard ››

Tenet Fintech Group Inc.

Tenet Fintech Group Inc.

Tenet Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) and artificial ...
View More »